🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RACE, #ARWR, #UWMC, #CX, #BMRN

#OptionFlow #OptionsTrading #Trading

U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) Treatment with PALYNZIQ led to statistically significant blood phenylalanine lowering compared to diet alone in pivotal Phase 3 PEGASUS study. PALYNZIQ is the only enzyme substitution therapy approved for the treatment of people with PKU. SAN RAFAEL, Calif., Feb. 27, 2026/ PRNewswire/-- BioMarin Pharmaceutical Inc. today announced that the U.S. Food and Drug...

#BMRN U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

www.stocktitan.net/news/BMRN/u-s-food-and-d...

#BMRN #FOLD #f46800fe-b310-442c-af78-430d7c3d2875 #investing #Health #Care

Origin | Interest | Match

BioMarin Completes Pricing of Senior Notes and New Loan Facility for Amicus Acquisition BioMarin Pharmaceutical announces the pricing of $850 million in senior unsecured notes and a $2 billion term loan to fund its Amicus acquisition.

BioMarin Completes Pricing of Senior Notes and New Loan Facility for Amicus Acquisition #BioMarin #BMRN #Amicus

#V #BMRN #META #UNH #NEE #ORLY #YORW #TTD #OKTA #SIRI #3fce2422-cc31-4b3c-8c2d-fb0145d28a15

Origin | Interest | Match

#V #BMRN #META #UNH #NEE #ORLY #YORW #TTD #OKTA #SIRI #3fce2422-cc31-4b3c-8c2d-fb0145d28a15

Origin | Interest | Match

Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results - Autozi Internet Tech (NASDAQ:AZI), BlackBerry (NYSE:BB)

Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results read more

#AZI #BB #BMRN #Earnings #FOLD #LW #MGRX #Mid #Day #Market #Update

Origin | Interest | Match

#CDTX #MRK #BMRN #NKTR #e9b5d92d-cc59-43a7-b71e-fe0e2c65eae0 #investing #Health #Care

Origin | Interest | Match

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook. 2025 Year-to-date Total Revenues Increased 11% Y/Y Led by More Than 20% Revenue Growth for PALYNZIQ and VOXZOGO. SAN RAFAEL, Calif., Oct. 27, 2025/ PRNewswire/-- BioMarin Pharmaceutical Inc. today announced financial results for the third quarter ended...

#BMRN BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

www.stocktitan.net/news/BMRN/bio-marin-repo...

BioMarin Pharmaceutical Announces Key Participation in September Investor Conferences BioMarin Pharmaceutical is set to present at several key investor conferences in September, highlighting their innovative therapies and pipeline.

BioMarin Pharmaceutical Announces Key Participation in September Investor Conferences #United_States #San_Rafael #biotechnology #BioMarin #BMRN

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter - ARM Holdings (NASDAQ:ARM), Booking Holdings (NASDAQ:BKNG) Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Hedge Fund Elliott Management's Q2 Moves Include Positions Tied To S&P 500, Nasdaq, Nvidia (CORRECTED) Hedge fund Elliott Management revealed a Q2 portfolio reshuffle, adding new positions ...

#ARM #BKNG #BMRN #Chip #Stocks #CRMD #CSCO #DLR #Elliott #Management #ETWO

Origin | Interest | Match

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter - ARM Holdings (NASDAQ:ARM), Booking Holdings (NASDAQ:BKNG) Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter Elliott Management places new bets against the market in the second quarter, while taking a new long position...

#ARM #BKNG #BMRN #Chip #Stocks #CRMD #CSCO #DLR #Elliott #Management #ETWO

Origin | Interest | Match

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter - ARM Holdings (NASDAQ:ARM), Booking Holdings (NASDAQ:BKNG) Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter Elliott Management places new bets against the market in the second quarter, while taking a new long position...

#ARM #BKNG #BMRN #Chip #Stocks #CRMD #CSCO #DLR #Elliott #Management #ETWO

Origin | Interest | Match

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter - ARM Holdings (NASDAQ:ARM), Booking Holdings (NASDAQ:BKNG) Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter Elliott Management places new bets against the market in the second quarter, while taking a new long position...

#ARM #BKNG #BMRN #Chip #Stocks #CRMD #CSCO #DLR #Elliott #Management #ETWO

Origin | Interest | Match

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS BioMarin (NASDAQ:BMRN) reported strong Q2 2025 results with total revenues of $825 million, up 16% year-over-year. The company achieved GAAP EPS of $1.23 (+124% Y/Y) and Non-GAAP EPS of $1.44 (+50% Y/Y).Key highlights include VOXZOGO revenue growth of 20% and Enzyme Therapies revenue growth of 15%. The company completed the acquisition of Inozyme in July 2025, adding BMN 401 to its portfolio. Additionally, BMN 333, their long-acting CNP for achondroplasia, showed promising results in healthy volunteer studies.Based on strong performance, BioMarin raised its full-year 2025 guidance for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS. The company ended Q2 with $1.9 billion in cash and investments.

#BMRN BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

www.stocktitan.net/news/BMRN/bio-marin-repo...

BioMarin Announces Completion of Acquisition of Inozyme BioMarin Pharmaceutical (Nasdaq: BMRN) has completed its acquisition of Inozyme Pharma (Nasdaq: INZY) in an all-cash transaction valued at approximately $270 million, or $4.00 per share. The tender offer, which expired on June 30, 2025, resulted in approximately 70% of Inozyme shares being validly tendered.The strategic acquisition strengthens BioMarin's enzyme therapies portfolio by adding INZ-701, a late-stage enzyme replacement therapy. This investigational treatment targets ENPP1 Deficiency, a rare genetic condition affecting blood vessels, soft tissues, and bones. INZ-701 is designed to restore pyrophosphate and adenosine levels and has potential applications in additional indications including ABCC6 Deficiency and calciphylaxis.Following the merger completion, Inozyme shares have ceased trading on the Nasdaq Global Select Market and will be delisted. The Boston-based Inozyme, with approximately 50 employees, brings expertise in the PPi-Adenosine Pathway research and development to BioMarin's established portfolio of eight commercial therapies.

#BMRN #INZY BioMarin Announces Completion of Acquisition of Inozyme

www.stocktitan.net/news/BMRN/bio-marin-anno...

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma BioMarin Pharmaceutical (BMRN) has announced the acquisition of Inozyme Pharma for $4.00 per share in an all-cash transaction valued at approximately $270 million. The deal adds INZ-701, a Phase 3 enzyme replacement therapy being developed for ENPP1 Deficiency, to BioMarin's enzyme therapies portfolio. INZ-701 could become the first treatment for this rare genetic condition that affects blood vessels, soft tissues, and bones. The first Phase 3 pivotal data readout in children is expected in early 2026, with potential launch in 2027. The transaction, unanimously approved by both companies' boards, is expected to close in Q3 2025. Phase 1/2 study results showed a favorable safety profile with improvements in pyrophosphate levels, bone mineralization biomarkers, and quality of life.

#BMRN #INZY BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

www.stocktitan.net/news/BMRN/bio-marin-stre...

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings BioMarin presented new data for VOXZOGO® (vosoritide) showing promising results in treating children with achondroplasia and other skeletal conditions. Key findings include: Treatment demonstrated significant reduction in tibial bowing compared to placebo in children with achondroplasia, with sustained improvement over several years. Modeling indicated potential final height increases of 21.7 cm in girls and 26.4 cm in boys compared to untreated children when treated early and continuously. A large retrospective study of over 600 patients with hypochondroplasia revealed higher rates of comorbidities, surgeries, and doctor visits compared to those without the condition. Additionally, early data from a Phase 2 trial showed promising increases in annualized growth velocity for girls with Turner syndrome, even in those who previously had suboptimal results with human growth hormone. BioMarin has completed enrollment in its pivotal Phase 3 study for VOXZOGO in hypochondroplasia, with topline data expected in 2026 and potential launch in 2027.

#BMRN BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

www.stocktitan.net/news/BMRN/bio-marin-pres...

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance First Quarter 2025 Total Revenues of $745 million. First Quarter 2025 GAAP Diluted Earnings Per Share of $0.95. First Quarter 2025 Non-GAAP Diluted EPS of $1.13.

#BMRN BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

www.stocktitan.net/news/BMRN/bio-marin-repo...

www.fool.com/investing/2025/04/11/6-s...

#PFE #INTC #BMRN #FSLY #PUBM […]

[Original post on fool.com]

Breakthrough: PALYNZIQ Shows Powerful Results in Teen PKU Patients, Opening New Market Clinical trial success expands PALYNZIQ's potential to adolescent PKU patients, showing significant blood Phe reduction vs diet alone. Full efficacy data inside.

#BMRN BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

www.stocktitan.net/news/BMRN/bio-marin-anno...

Can BioMarin's 18% Revenue Surge and Pipeline Progress Reshape Its Growth Story? Q4 earnings showcase 16% revenue growth, expanded margins, and 260% jump in operating cash flow. Pipeline advancement signals continued momentum.

#BMRN BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

www.stocktitan.net/news/BMRN/bio-marin-repo...

HeatMaps - ORTEX

📈 Post-Market Earnings Reports!

#CAKE, #CDE, #CF, #CVNA, #BMRN, #NDSN, #TOST and more set to release earnings.

Stay ahead of the trends with ORTEX’s Earnings Heat Map!

app.ortex.com/earnings/hea...

#Earnings #Heatmap #MarketWatch #Investing #ORTEX

BioMarin Takes Legal Action Against Ascendis Over CNP Patent in European Court BioMarin Pharmaceutical initiates patent infringement lawsuit against Ascendis Pharma in Munich's Unified Patent Court over long-acting CNP variants, with ruling expected in 2025.

#BMRN BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

www.stocktitan.net/news/BMRN/bio-marin-anno...